Skip to content

AARD AARD Stock-Based Comp

Stock-Based Comp at other companies

AbbVie logo
AbbVieABBV
$444M+8.3%
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$956.19K-73.2%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$23.1M+79.6%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$2.32M+46.1%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$10.34M-8.9%
Arvinas logo
ArvinasARVN
$12.1M-19.3%

Other financials

Income statement

See full
Revenue-
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation

See full
Market cap$124.35M-58.6%
Enterprise value$62.25M-77.4%

Returns & leverage

See full
Return on equity-58.8%
Debt / equity0.0×
Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AARD's stock-based comp?
AARD (AARD) reported stock-based comp of $2M in Q1 2026.
How has AARD's stock-based comp changed year-over-year?
AARD's stock-based comp increased by 760.1% year-over-year, from $233K to $2M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.